The aim of the study was to investigate whether or not the addition of a DPP4-inhibitor to start of insulin treatment could lead to lower exogenous insulin requirements together with lower glucose variability, less weight gain, less hypoglycemia, and improved insulin and glucagon dynamics after a mixed meal test through improvement in alpha and beta cell function. Here, GCG is linked to Hypoglycemia.